The Evolving Molecular Landscape and Actionable Alterations in Urologic Cancers

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• The genetic basis of urologic cancers is increasingly understood.
• Actionable mutations influence cancer diagnosis, prognosis, and treatment.
• Key urologic cancers include bladder, renal, prostate, testicular, and penile.

Purpose of the Study:

• To review and consolidate current literature on genetic mutations in urologic cancers.
• To highlight the role of specific genetic alterations and pathway dysregulations.
• To emphasize the importance of precision oncology and emerging therapies.

Main Methods:

• Narrative review of existing scientific literature.
• Focus on genetic mutations in DNA damage repair genes (e.g., BRCA1/2, PTEN).
• Analysis of pathway alterations (e.g., FGFR, PD-L1 overexpression).

Main Results:

• Identified mutations in DNA damage repair genes and pathway alterations across urologic cancers.
• Molecular profiling via next-generation sequencing enables targeted treatments for subtypes like basal/luminal bladder cancer and clear cell renal carcinoma.
• Emerging therapies like FGFR inhibitors and immune checkpoint blockade show promise.

Conclusions:

• Genetic mutations significantly impact urologic cancer behavior and treatment response.
• Precision oncology approaches guided by molecular profiling are crucial for personalized management.
• Further research into genetic landscapes is essential for developing novel, individualized therapies.